FDA Refuse to File (RTF): The Rejection Before the Review

The Rejection That Comes Before the Review

Most investors know about the Complete Response Letter — the FDA's notice that it will not approve a drug after reviewing it. Fewer know about the Refuse to File (RTF), which is the FDA declining to begin a substantive review at all.

After a sponsor submits a New Drug Application or Biologics License Application, the FDA performs an initial filing review, usually within 60 days, to decide whether the application is complete enough to evaluate. If it is not, the agency issues an RTF.

What Triggers an RTF

An RTF is about completeness and basic adequacy, not the ultimate merits. Common triggers include:

• Missing or incomplete sections (clinical, manufacturing, or nonclinical).
• A clinical package the FDA judges inadequate on its face — for example, a single trial where the agency expected two, or an endpoint that does not support the claimed indication.
• Significant data-quality or formatting deficiencies.

Crucially, an RTF can reflect a disagreement about the sufficiency of the evidence, not just clerical gaps. That is why it can be a more serious signal than it first appears.

RTF vs. Complete Response Letter

The distinction matters:

• Refuse to File happens before review. The FDA never started the formal evaluation; the PDUFA clock does not run.
• Complete Response Letter happens after a full review, listing the deficiencies that prevented approval.

An RTF is earlier and, in some ways, more fundamental — it suggests the application was not ready to be reviewed in the first place. The company can address the FDA's concerns and resubmit, but it has lost time and signaled an execution or strategy gap.

What It Signals to Investors

An RTF is generally a negative surprise, and the market treats it as such. The key follow-up questions are:

1. Was it procedural or substantive? A formatting fix is recoverable quickly. A dispute over whether the clinical evidence supports approval is a deeper problem.
2. How long is the delay? Resubmission resets the timeline and pushes back any potential revenue, which strains a thin cash runway.
3. Does the company have a clear path back? Management's explanation — and whether it aligns with prior FDA feedback — tells you a lot about execution quality.

How to Reduce the Surprise

RTFs are often foreshadowed. Companies that skip an end-of-Phase-2 meeting, proceed despite ambiguous FDA feedback, or rely on a single trial in a setting where the FDA expects more, carry higher RTF risk. Reading a company's regulatory history and prior FDA interactions — the kind of detail captured in SEC filings and disclosed program updates — helps you anticipate it.

The Bottom Line

A Refuse to File is the FDA saying "this isn't ready to review." It is earlier and rarer than a Complete Response Letter, and because it can reflect a substantive disagreement about evidence, it deserves careful reading rather than a reflexive "it's just procedural." Track the FDA decisions and resubmission timelines for the companies you follow on the FDA calendar and their company pages.